Anakinra treatment in patients with systemic-onset juvenil idiopathic arthritis: “The Valencia Experience”

Methods We retrospectively reviewed the medical records of patients with SoJIA treated with anakinra (1-3 mg/kg/ day) in our unit between December 2004 and july 2010. Anakinra’s effects were studied on several parameters including fever, rash, erythrocyte sedimentation rate, Creactive protein levels, arthritis joints count, assessment of disease activity (by physician and parent/patient) and pain (by parent/patient). Resulting data were analysed to characterize therapies, clinical course and adverse events.